Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 8/20 | 0.70 |
| ▸ | ACKR3 | P25106 | 4/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.46 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 3/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.45 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.44 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7933183 | 0.89 | BACE1 (0.71) | BACE1GRM4HDAC3NCOR1AURKA | |
| SCHEMBL7944661 | 0.89 | BACE1 (0.71) | BACE1ACKR3GRM4AURKARPS6KB1 | |
| SCHEMBL7944667 | 0.88 | BACE1 (0.70) | BACE1AURKARPS6KB1AURKB | |
| SCHEMBL7933424 | 0.88 | BACE1 (0.73) | BACE1GRM4HDAC3NCOR1AURKA | |
| SCHEMBL7942377 | 0.87 | BACE1 (0.67) | BACE1ACKR3AURKAAURKB | |
| SCHEMBL7942219 | 0.86 | BACE1 (0.60) | BACE1GRM4AURKARPS6KB1AURKB | |
| SCHEMBL12301753 | 0.86 | BACE1 (0.76) | BACE1GRM4HDAC3NCOR1AURKA | |
| SCHEMBL7939305 | 0.86 | BACE1 (0.52) | BACE1GRM4HDAC3HDAC1HDAC2 | |
| SCHEMBL7940722 | 0.86 | BACE1 (0.76) | BACE1GRM4HDAC3NCOR1AURKA | |
| SCHEMBL7942385 | 0.85 | BACE1 (0.67) | BACE1GRM4AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237576-A1 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| WO-2010047372-A1 | 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY | 塩野義製薬株式会社 (JP) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237576-A1 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY | BACE1, APP, BACE2 | BACE1 1/4885ACKR3 3283/4885GRM4 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.